Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who have a chronic subdural hematoma (a blood collection between the brain and its outer covering) on one or both sides of the head that is causing symptoms, and where scans show it is mostly dark or grey in appearance — requiring a specific type of surgery called burr-hole evacuation with drainage (a small hole is made in the skull to drain the blood)
- People who are currently taking a blood-thinning tablet (oral anticoagulant) because of a heart rhythm condition called atrial fibrillation (an irregular heartbeat), which was diagnosed before this episode
- People whose enrolment into the trial happens within 4 days of their surgery
Who may not be able to join:
- People who experience a bleeding complication during or immediately after surgery
- People whose condition requires a more extensive brain surgery (such as opening a larger part of the skull) rather than the smaller burr-hole procedure
- People who have had surgery for the same type of blood collection within the past 12 months
- People who have a cerebrospinal fluid shunt (a tube surgically placed to drain fluid from the brain)
- People whose blood collection is located inside a fluid-filled sac in the brain called an arachnoid cyst
- People where surgery reveals the collected fluid is cerebrospinal fluid (the fluid that surrounds the brain) rather than blood
- People who need blood-thinning treatment for a reason other than atrial fibrillation — for example, blood clots in the lungs or legs, or a clotting disorder
- People who have a mechanical (artificial) heart valve
- People with moderate or severe narrowing of the mitral heart valve (a specific heart valve condition)
- People for whom blood-thinning medication is not considered safe — for example, due to a bleeding disorder, a high risk of serious falls (such as from severe alcohol dependence), very low platelet count, or severe anaemia
- People currently taking antiplatelet medication (a different type of blood-thinning tablet, such as aspirin or clopidogrel)
- People with moderate to severe kidney problems (confirm with trial site for specific test values)
- People who are not permanent residents of Finland (for the Finnish part of the trial) or not permanent residents of the Stockholm region (for the Swedish part of the trial)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rahul Raj, MD, PhD, Helsinki University Hospital & University of Helsinki
Phone: +358504272516
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of composite outcome of vascular events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.